Kaitlyn Bader is a Senior Editor at Managed Healthcare Executive. She specializes in medicine and healthcare, with a focus on topics such as dermatology, endocrinology, immunology, and mental health care. Kaitlyn's work has been featured in publications including Managed Healthcare Executive, AJMC - The American Journal of Managed Care, Drug Topics, and Dermatology Times.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kaitlyn Bader's coverage focuses on healthcare, pharmaceuticals, and scientific developments within the field of dermatology. She regularly cites data and includes expert commentary, indicating a preference for evidence-based insights from professionals in the medical and pharmaceutical fields.
Given her focus on specific medical conditions, drug trials, and research breakthroughs in dermatology, Kaitlyn would likely value pitches that offer access to experts directly involved in the research or development of treatments for skin conditions. Additionally, she might be interested in interviews with clinicians who have extensive experience treating these conditions or researchers with unique findings related to dermatological issues.
As geographic focus is not specified but given the nature of medical research being global by default unless stated otherwise; consider offering international perspectives or examples when pitching relevant stories to Kaitlyn.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kaitlyn Bader, Jared Gollob
Jared Gollob, MD, chief medical officer at Kymera Therapeutics, discusses early efficacy signals, the phase 2b study design, and the potential clinical role of KT-621, an oral STAT6 degrader, for moderate to severe atopic dermatitis.
By: Kaitlyn Bader
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
By: Kaitlyn Bader, Elizabeth Buzney
Elizabeth Buzney, MD, provides her advice for practice setup, prior authorization timelines, and patient counseling for afamelanotide treatment in erythropoietic protoporphyria.
By: Kaitlyn Bader, David Rosmarin
At RAD 2026, David Rosmarin, MD, discussed the unmet need in chronic hand eczema, emerging pipeline agents, and his approach to evaluating clinical trial data.
By: Kaitlyn Bader, David Rosmarin
David Rosmarin, MD, reviewed the heterogeneous nature of chronic hand eczema, areas of unmet need in atopic dermatitis treatment, and emerging systemic options in the vitiligo pipeline at RAD 2026.
By: Kaitlyn Bader
Derm-Biome Pharmaceuticals reported positive preclinical results for DB-006, a small molecule reducing itch, inflammation, and IgE levels in a model of atopic dermatitis.
By: Kaitlyn Bader, Peter Lio
At RAD 2026, Peter Lio, MD, discussed shared decision-making strategies and emerging microbiome-targeted therapies for atopic dermatitis.
By: Kaitlyn Bader
Neal Bhatia, MD, led an Evolving Paradigms event on advancing multidisciplinary care in cutaneous squamous cell carcinoma to compare systemic immunotherapy data and referral practices.
By: Kaitlyn Bader
Verrica Pharmaceuticals and Japanese partner Torii Pharmaceutical have each dosed a first patient in COVE-3, the second pivotal phase 3 trial testing Ycanth for common warts.
By: Kaitlyn Bader
A recent JAAD case report describes congenital depigmentation and progressive post-transplant repigmentation in a child with NHEJ1-related radiosensitive SCID, a pairing not previously documented.
